Skip to content

Effect of Iranian Traditional Medicine Remedy on Chemotherapy Induced Nausea and Vomiting

ٍEffect of Iranian Traditional Medicine Remedy Compared With Placebo on Chemotherapy Induced Nausea and Vomiting in Breast Cancer; a Double-blind Randomized Controlled Cross-over Clinical Trial

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02787707
Enrollment
69
Registered
2016-06-01
Start date
2015-10-31
Completion date
2016-05-31
Last updated
2016-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea, Vomiting

Keywords

Breast cancer, Traditional medicine, Chemotherapy Induced Nausea and Vomiting, Bunium Persicum, Rhus Coriaria

Brief summary

The main objective of this research is the role of the Persumac(an Iranian traditional remedy) on refractory Chemotherapy Induced Nausea and Vomiting (CINV) in breast cancer patients. Investigators assess effect of Persumac on the number/severity of nausea/ vomiting in acute and delayed phase.

Detailed description

The study was a double-blind, placebo controlled, Cross-over clinical trial of Iranian traditional remedy (Persumac) on chemotherapy induced nausea and vomiting in breast cancer patients. From October 2015 to May 2016, sample selection continued to be until the full sample size. Executive steps of study: 1. Among patients referred for breast cancer, to the oncology clinic in Imam Reza hospital in Mashhad University of Medical Sciences, an oncology referral center in the North East of Iran; patients included in study who had at least one chemotherapy session and remain at least three sessions of Their chemotherapy cycle and had inclusion criteria. 2. The initial assessment of patients (Run- in): Concurrent with the visit of patient for chemotherapy (the first session of her/his chemotherapy in this study); during interview, study questionnaire was delivered to patient. It took a full explanation of how to complete it and return the next session. 3. In the second session of chemotherapy (in study); after eligibility qualification and obtaining consent form, patients randomly allocated into intervention and control groups, In accordance with the study protocol, interventions take place. Questionnaire was delivered to the patient again. 4. (Wash out): Sixth day after the second session of chemotherapy until a day before the third session of chemotherapy determined as Wash out period. 5. In the third session of chemotherapy-in study, after obtaining the previous questionnaire, patient received cross over interventions. Questionnaire delivered to the patient again.

Interventions

DRUGPersumac

2.7 grams Persumac powder (Iranian traditional medicine remedy composed from sumac and Bunium Persicum) every 8 hour

DRUGlactose

2.7 grams Lactose every 8 hour

Sponsors

Mashhad University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of breast cancer, * Clinical diagnosis of chemotherapy induced nausea and vomiting resistant to conventional therapy.

Exclusion criteria

* Clinical diagnosis of hypersensitivity to Sumac or Bunium Persicum, * Clinical diagnosis of digestion disorders, * Clinical diagnosis of non chemotherapy induced nausea and vomiting, * Milk allergy, * Clinical diagnosis of bleeding diathesis, * Clinical diagnosis of non-breast cancer.

Design outcomes

Primary

MeasureTime frameDescription
Frequency and Severity of nausea and vomiting in acute phasefirst 24 hour after chemotherapynumber and severity of nausea and vomiting, acquired from questionnaire

Secondary

MeasureTime frameDescription
Frequency and Severity of nausea and vomiting in acute phaseDay 2-5 of chemotherapynumber and severity of nausea and vomiting, acquired from questionnaire

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026